Drug Profile
Research programme: biotherapeutics - Greenovation Biotech
Alternative Names: Moss-alpha-glucosidase; Moss-factor H; Moss-FH; Moss-GAA; Moss-GBA; Moss-glucerase; Moss-glucocerebrosidaseLatest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator Greenovation Biotech
- Class Enzymes; Recombinant proteins
- Mechanism of Action Alpha glucosidase replacements; Complement system protein replacements; Glucosylceramidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gaucher's disease; Glycogen storage disease type II; Haemolytic uraemic syndrome
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for preclinical development in Gaucher's-disease in Germany
- 28 Jun 2020 No recent reports of development identified for preclinical development in Haemolytic-uraemic-syndrome in Germany
- 28 Jun 2020 No recent reports of development identified for research development in Glycogen-storage-disease-type-II in Germany